CNW/ – This week, The New England Journal of Medicine (NEJM) published results from Novo Nordisk’s phase 3 REDEFINE 1 trial ...

CagriSema is delivered as a once-weekly subcutaneous injection, like Wegovy and Zepbound, and Novo Nordisk also presented data at ADA on its oral weight-loss candidate amycretin, which combines ...

W. Timothy Garvey, M.D., served as lead author in the clinical trial. A new combination drug therapy is showing extraordinary ...

Eli Lilly is a leader in the weight management market, with only a single worthy challenger. The pharmaceutical giant has a ...

A fast-growing group of Americans are turning to what many call the "gray market" for obesity medicines, bringing cheap ...

Taking to platforms including Reddit and Telegram for guidance, buyers import small quantities, often described as research ...

Novo Nordisk shares fell due to a supply issue in the US, disappointing trial results for its new weight loss drug CagriSema, and heightened competition. The trust declared an interim dividend of 1.4p ...

Novo Nordisk shares have come under pressure amid weight-loss drug competition, while UK health officials have launched a ...

We came across a bullish thesis on Novo Nordisk A/S on Kontra Investments’ Substack by Kontra. In this article, we will ...

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...

Novo Nordisk NVO announced that it has ended its collaboration with telehealth provider Hims & Hers Health. In addition, the ...

Combination therapy with a long-acting amylin analogue and a glucagon-like peptide-1 (GLP-1) receptor agonist results in ...